QCG
BCAB icon

Quadrant Capital Group’s BioAtla BCAB Stock Holding History

Quadrant Capital Group’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20
Closed -$29K – 2509
2021
Q3 		$29K Hold
20
– – ﹤0.01% 1078
2021
Q2 		$42K Hold
20
– – 0.01% 904
2021
Q1 		$51K Sell
20
-4
-17% -$10.3K 0.01% 800
2020
Q4 		$41K Buy
+24
New +$40.1K 0.01% 811

Other funds holding BCAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Quadrant Capital Group's BCAB Position: Q4 2021 in Review

Quadrant Capital Group sold out of BioAtla (BCAB) in Q4 2021, closing a stake of 20 shares — an estimated $29K sold.

Quadrant Capital Group first reported a position in BCAB in Q4 2020 and held it in 4 quarters. The position peaked at $51K in Q1 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2021.

  • Quadrant Capital Group reported no remaining BioAtla position as of Q4 2021 after selling out during the quarter.
  • Quadrant Capital Group sold 20 BioAtla shares in Q4 2021, an estimated $29K.
  • Quadrant Capital Group first reported a position in BioAtla in Q4 2020 and held it in 4 quarters.
  • Quadrant Capital Group's BioAtla position peaked at $51K in Q1 2021.
  • 79 funds tracked by Wall St. Rank held BioAtla as of Q4 2021.

Based on Quadrant Capital Group's 13F filing for Q4 2021, filed 1 Feb 2022.